Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

BACKGROUND: Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate cancer are associated with long-term toxic effects, including osteoporosis. Use of parenteral oestrogen could avoid the long-term complications associated with LHRHa and the thromboembolic complications associated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Langley, Ruth E, Cafferty, Fay H, Alhasso, Abdulla A, Rosen, Stuart D, Sundaram, Subramanian Kanaga, Freeman, Suzanne C, Pollock, Philip, Jinks, Rachel C, Godsland, Ian F, Kockelbergh, Roger, Clarke, Noel W, Kynaston, Howard G, Parmar, Mahesh KB, Abel, Paul D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3620898/
https://www.ncbi.nlm.nih.gov/pubmed/23465742
http://dx.doi.org/10.1016/S1470-2045(13)70025-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3620898/
https://www.ncbi.nlm.nih.gov/pubmed/23465742
http://dx.doi.org/10.1016/S1470-2045(13)70025-1

Ejemplares similares